INTRANASAL SPRAY-TYPE TUBERCULOSIS VACCINE USING PARAMYXOVIRUS VECTOR
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
N/A
app pub date -
Nov 1, 2010
filing date -
Nov 2, 2009
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
Disclosed is a intranasal spray-type tuberculosis vaccine, which has a high prophylactic effect on human tuberculosis, particularly adult tuberculosis. The nebulizable tuberculosis vaccine for intranasal administration comprises a paramyxovirus gene (particularly rhPIV2) having, integrated therein, a gene encoding an α antigen derived from an acid-fast bacterium (e.g., an α antigen derived from Mycobacterium kansasii or Mycobacterium bovis BCG), an analogue of the gene, or a variant of the gene which has an equivalent function to that of the gene.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully